Literature DB >> 22329760

Study of clinical, biochemical and immunological factors determining stability of disease in patients with generalized vitiligo undergoing melanocyte transplantation.

A Rao1, S Gupta, A K Dinda, A Sharma, V K Sharma, G Kumar, D K Mitra, C K Prashant, G Singh.   

Abstract

BACKGROUND: Stability is considered the most important parameter before performing any melanocyte transplantation procedure in vitiligo; however, current criteria rely on the history given by the patients.
OBJECTIVE: This study was undertaken to determine the clinical, biochemical and immunological factors determining stability of disease in patients with generalized vitiligo to facilitate better patient selection for melanocyte transplantation and to understand immunological mechanisms for disease activity.
METHODS: Thirty-three patients with generalized vitiligo with < 10% body surface area involved were allocated to three clinical stability groups: Group 1 (stability > 3 months but < 1 year), Group 2 (≥ 1 year but < 2 years) and Group 3 (≥ 2 years). Melanocyte transplantation was done using suction blister epidermal grafting (SBEG) on a single patch. Blood was drawn for catalase estimation from all patients and from 10 healthy control subjects. A 3-mm punch biopsy was taken on the day of transplantation from the margin of the macule in the first five patients in each group for the immunohistochemistry of CD4, CD8, CD45RO, CD45RA and FoxP3. Those with ≥ 75% repigmentation at 6 months were labelled as responders.
RESULTS: The success rate was 0% in Group 1, 37·5% in Group 2 and 77·8% in Group 3. The difference in the success rate between the groups was statistically significant (P = 0·005). The median period of stability was significantly higher in the responders compared with that in the nonresponders (P = 0·001). Catalase levels were not significantly different between patients in the three groups of cases and in controls, or between responders and nonresponders. Lesional CD8 cells were significantly higher in Group 1 compared with Group 3. The percentages of CD8 and CD45RO cells were significantly higher in the nonresponders compared with the responders.
CONCLUSION: Along with clinical stability, the proportion of CD8 and CD45RO cells in skin biopsies might help to determine the stability of the disease and thereby predict the success of transplantation.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22329760     DOI: 10.1111/j.1365-2133.2012.10886.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

1.  Non-cultured melanocyte/keratinocyte transplantation for the treatment of stable vitiligo on the face: report of two cases.

Authors:  Mariana Gontijo Ramos; Daniel Gontijo Ramos; Gabriel Gontijo; Camila Gontijo Ramos; Tania Nely Rocha; Rafael Henrique Rocha
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

2.  Efficacy of Transplantation of Combination of Noncultured Dermal and Epidermal Cell Suspension vs Epidermal Cell Suspension Alone in Vitiligo: A Randomized Clinical Trial.

Authors:  Vishal Thakur; Sheetanshu Kumar; Muthu Sendhil Kumaran; Hitaishi Kaushik; Niharika Srivastava; Davinder Parsad
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

3.  Combination of Follicular and Epidermal Cell Suspension as a Novel Surgical Approach in Difficult-to-Treat Vitiligo: A Randomized Clinical Trial.

Authors:  Muhammed Razmi T; Ravinder Kumar; Seema Rani; Sendhil M Kumaran; Sushma Tanwar; Davinder Parsad
Journal:  JAMA Dermatol       Date:  2018-03-01       Impact factor: 10.282

4.  The concept of stability of vitiligo: a reappraisal.

Authors:  Koushik Lahiri; Subrata Malakar
Journal:  Indian J Dermatol       Date:  2012-03       Impact factor: 1.494

Review 5.  Stability in Vitiligo: Is there a Perfect Way to Predict it?

Authors:  Kanika Sahni; Davinder Parsad
Journal:  J Cutan Aesthet Surg       Date:  2013-04

6.  A new era of vitiligo research and treatment.

Authors:  Davinder Parsad
Journal:  J Cutan Aesthet Surg       Date:  2013-04

Review 7.  Grafting in vitiligo: how to get better results and how to avoid complications.

Authors:  Imran Majid
Journal:  J Cutan Aesthet Surg       Date:  2013-04

8.  Dermal mesenchymal stem cells (DMSCs) inhibit skin-homing CD8+ T cell activity, a determining factor of vitiligo patients' autologous melanocytes transplantation efficiency.

Authors:  Miao-ni Zhou; Zhi-qing Zhang; Ji-long Wu; Fu-quan Lin; Li-fang Fu; Sui-qan Wang; Cui-ping Guan; Hong-lin Wang; Aie Xu
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 9.  Immunological Parameters Associated With Vitiligo Treatments: A Literature Review Based on Clinical Studies.

Authors:  Ana Cláudia Guimarães Abreu; Gabriela Guy Duarte; Juliana Yasmin Pains Miranda; Daniel Gontijo Ramos; Camila Gontijo Ramos; Mariana Gontijo Ramos
Journal:  Autoimmune Dis       Date:  2015-09-17

10.  Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report.

Authors:  Clarissa Luiza Dalla Bernardina Carvalho; Luciena Cegatto Martins Ortigosa
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.